Calithera Biosciences Research and Development Expenses 2013-2022 | CALA

Calithera Biosciences research and development expenses from 2013 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.

Calithera Biosciences Research and Development Expenses 2013-2022 | CALA

Calithera Biosciences research and development expenses from 2013 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$95B
Zoetis (ZTS)$66.3B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$41.7B
Summit Therapeutics (SMMT)$18.2B
Sandoz Group AG (SDZNY)$17.7B
Merck (MKKGY)$17.2B
Astellas Pharma (ALPMY)$16.9B
Shionogi (SGIOY)$14.1B
United Therapeutics (UTHR)$12.8B
Neurocrine Biosciences (NBIX)$10B
IPSEN (IPSEY)$8.6B
Orion OYJ (ORINY)$8B
Madrigal Pharmaceuticals (MDGL)$6.7B
Stevanato Group S.p.A (STVN)$6.6B
Corcept Therapeutics (CORT)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.8B
Ono Pharmaceutical (OPHLF)$5.5B
Grifols, S.A (GRFS)$4.9B
Ionis Pharmaceuticals (IONS)$4.5B
Soleno Therapeutics (SLNO)$3.2B
Crinetics Pharmaceuticals (CRNX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2.2B
Hypermarcas (HYPMY)$2.1B
NewAmsterdam Pharma (NAMS)$1.8B
Centessa Pharmaceuticals (CNTA)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B